UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                   ----------

                                    FORM 8-K

                                   ----------

                                 CURRENT REPORT

                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

        Date of Report (Date of earliest event reported): March 30, 2006

                                   ----------

                        BrainStorm Cell Therapeutics Inc.
             (Exact Name of Registrant as Specified in its Charter)

                                   ----------


        Washington                   333-61610                   912061053
(State or Other Jurisdiction  (Commission File Number)         (IRS Employer
    of Incorporation)                                       Identification No.)

                           1350 Avenue of the Americas
                            New York, New York 10019
               (Address of Principal Executive Offices) (Zip Code)

                                 (212) 557-9000
              (Registrant's telephone number, including area code)

                                 Not Applicable
          (Former name or former address, if changed since last report)

                                   ----------

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

|_|   Written communications pursuant to Rule 425 under the Securities Act (17
      CFR 230.425)

|_|   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)

|_|   Pre-commencement communications pursuant to Rule 14d-2(b) under the
      Exchange Act (17 CFR 240.14d-2(b))

|_|   Pre-commencement communications pursuant to Rule 13e-4(c) under the
      Exchange Act (17 CFR 240.13e-4(c))

--------------------------------------------------------------------------------


<PAGE>


Item 1.01 Entry into a Material Definitive Agreement.

         On March 30, 2006, BrainStorm Cell Therapeutics Inc. (the "Company")
entered into a Research and License Agreement (the "Amended Research and License
Agreement") with Ramot at Tel Aviv University Ltd. ("Ramot"), for the purpose of
amending and restating the Research and License Agreement (the "Original
Agreement") between the parties dated July 12, 2004. A copy of the Original
Agreement was filed with the Securities and Exchange Commission as Exhibit 10.1
to the Company's Form 8-K filed July 16, 2004.

         The Amended Research and License Agreement amends the period of time
that the Company has agreed to fund further research relating to the licensed
technology from an initial period of two years in the Original Agreement to an
initial period of three years. The Amended Research and License Agreement also
extends the additional two-year period in the Original Agreement to an
additional three-year period if certain research milestones are met. The Amended
Research and License Agreement provides for funding in the amount of $380,000
per year under this arrangement instead of $570,000 per year under the Original
Agreement. In addition, the Amended Research and License Agreement reduces
certain potential royalties that the Company may have to pay Ramot from five
percent (5%) to three percent (3%) of net sales. The Amended Research and
License Agreement also reduces certain payments of the Company in respect of
sublicenses from 30% to 20-25% of sublicense receipts.

         On March 31, 2006, the Company entered into an Amendment Agreement (the
"Amendment") with Ramot, Eldad Melamed, Daniel Offen, Yossef Levy and Pnina
Greene (together, the "Warrant Holders") relating to warrants to purchase an
aggregate of 12,800,845 shares of the Company's common stock at a purchase price
of $0.01 per share issued to the Warrant Holders on November 4, 2004 (the
"Warrants"). The Amendment extends the date by which the shares underlying the
Warrants must be registered by the Company for resale to no later than December
31, 2006. The Amendment also provides that replacement warrants with the amended
provision will be issued to the Warrant Holders within 30 days.

         On March 31, 2006, the Company also entered into an Amended and
Restated Registration Rights Agreement with the Warrant Holders (the "Amended
and Restated Registration Rights Agreement"). The Amended and Restated
Registration Rights Agreement amends and restates the Registration Rights
Agreement dated July 18, 2005 between the Company and the Warrant Holders. The
Amended and Restated Registration Rights Agreement amends the Effective Date (as
such term is defined in the Amended and Restated Registration Rights Agreement)
to December 31, 2006 and extends the date that the Company must file a
registration statement for the shares underlying the Warrants until July 1,
2006. The Amended and Restated Registration Rights Agreement also expands
piggyback rights to include registration statements filed for the benefit of
other shareholders.

         The  foregoing  description  details only the material  provisions  and
amendments  of the  agreements  and is subject to, and qualified in its entirety
by, the Amended  Research and License  Agreement,  the Amendment and the Amended
and Restated Registration Rights Agreement, each of which is filed as an exhibit
hereto and  incorporated  herein by reference.  The Form of Warrant that will be
issued to the  Warrant  Holders as the  replacement  warrant is also filed as an
exhibit hereto.


Item 9.01 Financial Statements and Exhibits.

(d)   Exhibits

10.1  Research and License Agreement, dated March 30, 2006 between the
      Registrant and Ramot at Tel Aviv University Ltd.

10.2  Amendment Agreement, dated March 31, 2006 between the Registrant, Ramot at
      Tel Aviv University Ltd. and the warrant holders set forth in Annex A
      therein.

10.3  Amended and Restated Registration Rights Agreement, dated March 31, 2006
      by and among the Registrant and the warrant holders listed on Schedule A
      thereto.

10.4  Form of Warrant to be issued as a replacement warrant under the Amendment
      Agreement.



<PAGE>


                                    SIGNATURE

      Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.



                                     BRAINSTORM CELL THERAPEUTICS INC.


                                     By: /s/ Yoram Drucker
                                         ------------------------------------
Date: April 4, 2006                      Yoram Drucker
                                         Chief Operating Officer
                                        (Principal executive officer)



<PAGE>



                                  EXHIBIT INDEX


Exhibit No.    Description
-----------    -----------

10.1           Research and License Agreement, dated March 30, 2006 between the
               Registrant and Ramot at Tel Aviv University Ltd.
10.2           Amendment Agreement, dated March 31, 2006 between the Registrant,
               Ramot at Tel Aviv University Ltd. and the warrant holders set
               forth in Annex A therein.
10.3           Amended and Restated Registration Rights Agreement, dated March
               31, 2006 by and among the Registrant and the warrant holders
               listed on Schedule A thereto.
10.4           Form of Warrant to be issued as a replacement warrant under the
               Amendment Agreement.
{"company-data": {"conformed-name": "BRAINSTORM CELL THERAPEUTICS INC", "cik": "0001137883", "assigned-sic": "2836", "irs-number": "912061050", "fiscal-year-end": "0331"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "333-61610", "film-number": "06737090"}, "business-address": {"street1": "1350 AVENUE OF THE AMERICAS", "city": "NEW YORK", "state": "NY", "zip": "10019", "phone": "250-519-0553"}, "mail-address": {"street1": "1350 AVENUE OF THE AMERICAS", "city": "NEW YORK", "state": "NY", "zip": "10019"}, "former-company": [{"former-conformed-name": "GOLDEN HAND RESOURCES INC", "date-changed": "20030827"}, {"former-conformed-name": "WIZBANG TECHNOLOGIES INC", "date-changed": "20010409"}]}
UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                   ----------

                                    FORM 8-K

                                   ----------

                                 CURRENT REPORT

                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

        Date of Report (Date of earliest event reported): March 30, 2006

                                   ----------

                        BrainStorm Cell Therapeutics Inc.
             (Exact Name of Registrant as Specified in its Charter)

                                   ----------

        Washington                   333-61610                   912061053
(State or Other Jurisdiction  (Commission File Number)         (IRS Employer
    of Incorporation)                                       Identification No.)

                           1350 Avenue of the Americas
                            New York, New York 10019
               (Address of Principal Executive Offices) (Zip Code)

                                 (212) 557-9000
              (Registrant's telephone number, including area code)

                                 Not Applicable
          (Former name or former address, if changed since last report)

                                   ----------

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

|_|   Written communications pursuant to Rule 425 under the Securities Act (17
      CFR 230.425)

|_|   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)

|_|   Pre-commencement communications pursuant to Rule 14d-2(b) under the
      Exchange Act (17 CFR 240.14d-2(b))

|_|   Pre-commencement communications pursuant to Rule 13e-4(c) under the
      Exchange Act (17 CFR 240.13e-4(c))

--------------------------------------------------------------------------------
Item 1.01 Entry into a Material Definitive Agreement.

         On March 30, 2006, BrainStorm Cell Therapeutics Inc. (the "Company")
entered into a Research and License Agreement (the "Amended Research and License
Agreement") with Ramot at Tel Aviv University Ltd. ("Ramot"), for the purpose of
amending and restating the Research and License Agreement (the "Original
Agreement") between the parties dated July 12, 2004. A copy of the Original
Agreement was filed with the Securities and Exchange Commission as Exhibit 10.1
to the Company's Form 8-K filed July 16, 2004.

         The Amended Research and License Agreement amends the period of time
that the Company has agreed to fund further research relating to the licensed
technology from an initial period of two years in the Original Agreement to an
initial period of three years. The Amended Research and License Agreement also
extends the additional two-year period in the Original Agreement to an
additional three-year period if certain research milestones are met. The Amended
Research and License Agreement provides for funding in the amount of $380,000
per year under this arrangement instead of $570,000 per year under the Original
Agreement. In addition, the Amended Research and License Agreement reduces
certain potential royalties that the Company may have to pay Ramot from five
percent (5%) to three percent (3%) of net sales. The Amended Research and
License Agreement also reduces certain payments of the Company in respect of
sublicenses from 30% to 20-25% of sublicense receipts.

         On March 31, 2006, the Company entered into an Amendment Agreement (the
"Amendment") with Ramot, Eldad Melamed, Daniel Offen, Yossef Levy and Pnina
Greene (together, the "Warrant Holders") relating to warrants to purchase an
aggregate of 12,800,845 shares of the Company's common stock at a purchase price
of $0.01 per share issued to the Warrant Holders on November 4, 2004 (the
"Warrants"). The Amendment extends the date by which the shares underlying the
Warrants must be registered by the Company for resale to no later than December
31, 2006. The Amendment also provides that replacement warrants with the amended
provision will be issued to the Warrant Holders within 30 days.

         On March 31, 2006, the Company also entered into an Amended and
Restated Registration Rights Agreement with the Warrant Holders (the "Amended
and Restated Registration Rights Agreement"). The Amended and Restated
Registration Rights Agreement amends and restates the Registration Rights
Agreement dated July 18, 2005 between the Company and the Warrant Holders. The
Amended and Restated Registration Rights Agreement amends the Effective Date (as
such term is defined in the Amended and Restated Registration Rights Agreement)
to December 31, 2006 and extends the date that the Company must file a
registration statement for the shares underlying the Warrants until July 1,
2006. The Amended and Restated Registration Rights Agreement also expands
piggyback rights to include registration statements filed for the benefit of
other shareholders.

         The  foregoing  description  details only the material  provisions  and
amendments  of the  agreements  and is subject to, and qualified in its entirety
by, the Amended  Research and License  Agreement,  the Amendment and the Amended
and Restated Registration Rights Agreement, each of which is filed as an exhibit
hereto and  incorporated  herein by reference.  The Form of Warrant that will be
issued to the  Warrant  Holders as the  replacement  warrant is also filed as an
exhibit hereto.

Item 9.01 Financial Statements and Exhibits.

(d)   Exhibits

10.1  Research and License Agreement, dated March 30, 2006 between the
      Registrant and Ramot at Tel Aviv University Ltd.

10.2  Amendment Agreement, dated March 31, 2006 between the Registrant, Ramot at
      Tel Aviv University Ltd. and the warrant holders set forth in Annex A
      therein.

10.3  Amended and Restated Registration Rights Agreement, dated March 31, 2006
      by and among the Registrant and the warrant holders listed on Schedule A
      thereto.

10.4  Form of Warrant to be issued as a replacement warrant under the Amendment
      Agreement.
SIGNATURE

      Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                     BRAINSTORM CELL THERAPEUTICS INC.

                                     By: /s/ Yoram Drucker
                                         ------------------------------------
Date: April 4, 2006                      Yoram Drucker
                                         Chief Operating Officer
                                        (Principal executive officer)
EXHIBIT INDEX

Exhibit No.    Description
-----------    -----------

10.1           Research and License Agreement, dated March 30, 2006 between the
               Registrant and Ramot at Tel Aviv University Ltd.
10.2           Amendment Agreement, dated March 31, 2006 between the Registrant,
               Ramot at Tel Aviv University Ltd. and the warrant holders set
               forth in Annex A therein.
10.3           Amended and Restated Registration Rights Agreement, dated March
               31, 2006 by and among the Registrant and the warrant holders
               listed on Schedule A thereto.
10.4           Form of Warrant to be issued as a replacement warrant under the
               Amendment Agreement.